Cogent Biosciences said its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Detailed price information for Verona Pharma Plc ADR (VRNA-Q) from The Globe and Mail including charting and trades.

In today's episode of *Blueprint Explosive Exclusive* with anchor Meghna Deka, the discussion revolves around the tragic death of Shefali Jariwala. A young, beautiful, and talented woman, Shefali rose ...

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.

Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint Medicines announced new data reinforcing the sustained clinical efficacy and ...

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines ...

STAT+ subscribers can sign up here to get it delivered to their inbox. Cogent Biosciences and Blueprint Medicines are direct competitors who hate each other.

Fintel reports that on June 17, 2025, Wells Fargo downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 0.45% Downside ...

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research note issued to investors on ...